MS and Demyelinating Disorders

The professor of neurology at Harvard Medical School provided some insight into her experience with treating pediatric patients with MS.

The pediatric critical care medicine attending physician in the Department of Anesthesiology and Critical Care Medicine at the Children’s Hospital of Philadelphia spoke about how physicians can better address brain death in pediatric patients.

The PDUFA date for the novel oral fumarate has been set for the fourth quarter of 2019. If approved, Biogen plans to commercialize the product under the trade name Vumerity.

The investigators wrote that these findings are suggestive of a superior effect of natalizumab and rituximab compared with fingolimod in suppressing further disease activity in patients with RRMS who switched from interferon or glatiramer acetate due to breakthrough disease.

The findings suggested that a patient’s likelihood of taking medications systematically decreased as the probability of potential AEs occurring increased or the efficacy of treatment decreased.

Neurology News Network for the week of February 23, 2019.

In a cohort study of 592 patients with MS, the findings were suggestive that real-world escalation approaches may be inadequate to prevent unfavorable long-term outcomes.

Over the past several years, scientific teams have developed investigational methods for delivering a gene to correct a mutation in the DMD gene which causes DMD by creating dysfunction in a patient’s dystrophin production.

A joint statement from the FDA commissioner and the director of the agency’s Center for Biologics Evaluation and Research noted the product is being offered at a variety of establishments as a treatment for conditions for which its benefits are unproven.